Self-reported periodontitis and C-reactive protein in Parkinson’s disease: a cross-sectional study of two American cohorts

Patricia Lyra1,2, João Botelho1,2, Vanessa Machado1,2, Silvia Rota3,4, Ryan Walker5, Juliet Staunton5, Luís Proença2,6, Kallol Ray Chaudhuri3,4 and José João Mendes1,2

Periodontitis triggers systemic repercussions, such as elevated levels of high-sensitive C-reactive protein (hs-CRP). This has never been studied within Parkinson’s Disease (PD). The aim of this study is to compare hs-CRP levels of self-reported periodontitis cases versus cases without periodontitis in PD patients. Data from the National Health and Nutrition Examination Survey (2015–2016 and 2017–2018 waves) were analyzed. PD cases were identified through medication regimens and periodontitis cases through a validated self-report questionnaire. 51 participants were included (24 females, 27 males, with mean age of 62.96 (14.71)). While the self-reported periodontitis group presented elevated levels of circulating hs-CRP (5.36 vs. 1.99 mg/L, p = 0.031), the self-reported without periodontitis group presented higher lymphocyte levels (29.35 vs. 28.03%, p = 0.007). Blood levels of hs-CRP were significantly higher in PD cases with self-reported periodontitis. Apart from the lymphocyte levels, there were no other significant differences according to the self-reported periodontal status. Future studies shall explore this association using clinical measures.

NPJ Parkinson’s Disease (2022) 8:40; https://doi.org/10.1038/s41531-022-00302-1

INTRODUCTION
Parkinson’s Disease (PD) is the fastest growing neurodegenerative movement disorder, affecting around 10 million people worldwide1,2. This chronic, progressive and degenerative condition of both the peripheral and central nervous systems3,4 is clinically heterogeneous, with various motor and non-motor clinical features5. It has been hypothesized that the onset and progression of PD, unclear thus far, is dependent on the conjugation of different key factors such as neuroinflammation, alpha-synuclein induced neuronal dysfunction (through intracellular aggregation into Lewy bodies, which stand as the pathological hallmark of PD), systemic chronic inflammation (translated in the dysregulation of circulating inflammatory cytokines) and even gut and periodontal dysbiosis6,7.

In the advanced stages, beyond the debilitating and interfering impact of motor and non-motor symptoms (NMS) on everyday-life activities, PD also has a major detrimental effect on patients’ overall quality of life8,9. Oral health is no exception and may be deteriorated in PD resulting from impaired oral hygiene and lack of oral care10,11. Among the possible oral conditions that may arise from inadequate oral care is periodontitis, a chronic, infectious, and inflammatory condition characterized by the destruction of the periodontium12. The physiopathology of periodontitis involves dental plaque dysbiosis and an uncontrolled immune response attacking the periodontal tissues13. Even though a clinical periodontal diagnosis is a gold standard, the self-report of periodontitis is an interesting epidemiological strategy that has been successfully developed and validated14–16. As an example, a recent prospective cohort study analyzed self-reported periodontitis relationship with female fecundability17, showing the potential of this self-reported measure in epidemiological scenarios.

The mutual link between PD and periodontitis has been studied recently. On the one hand, fine motor impairments and cognitive decline in PD patients compromise oral hygiene habits and general oral health status18,19. On the other hand, evidence has surged on bacterial inflammagons—including major virulence factors of key periodontal pathogens such as Porphyromonas gingivalis, like lipopolysaccharide (LPS) and gingipains—fueling a systemic inflammatory state that might be involved on the development of PD20–22. Furthermore, periodontitis was associated with a leukocytosis state in PD patients23. Also, higher blood levels of amyloid beta were found in periodontitis, mediated by inflammatory markers such as IL-6 and high-sensitive C-reactive protein (CRP)24. In fact, CRP is a widely evaluated non-specific inflammatory factor (CRP)25. In fact, CRP is a widely evaluated non-specific inflammatory marker in the clinical context, not only in the diagnosis and monitoring of acute inflammatory and infectious events but also in the management and prediction of chronic inflammatory conditions, such as cardiovascular and neurodegenerative diseases26,27. There are also increased levels of pro-inflammatory cytokines in PD, including CRP28. However, CRP levels have never been studied in PD cases according to their periodontal status, and this may provide useful information in the PD-periodontitis link regarding its systemic inflammatory burden.

Hence, we aimed to compare the hs-CRP levels of individuals with PD, according to their self-reported periodontal status.

RESULTS
Population
From the 19,225 evaluated participants of the 2015–2016 and 2017–2018 NHANES waves, 119 reported medication regimen...
The levels of biochemical parameters and complete blood count were analyzed in order to assess the systemic status of these participants according to the self-reported periodontal status (Table 2).

Overall, statistically significant differences were found for hs-CRP levels ($p = 0.031$) and lymphocyte percentage ($p = 0.007$). The “periodontitis” group presented higher mean levels of hs-CRP (5.36 vs. 1.99 mg/L) when compared to the “without periodontitis” group, while the “without periodontitis” group presented a higher mean percentage of lymphocytes when compared to the “periodontitis” group (29.35 vs. 28.03%).

In order to explore potential confounding variables on the hs-CRP levels, we observed that PD patients with diabetes mellitus ($p = 0.130$), hypertension ($p = 0.844$), coronary heart disease ($p = 0.405$), emphysema ($p = 0.365$), asthma ($p = 0.184$), hepatic conditions ($p = 0.888$) or cancer ($p = 0.354$) had non-significant differences in serum levels of this marker. Similarly, active smokers did not present significant differences in serum levels of hs-CRP ($p = 0.343$).

**Blood and biochemical parameters**

The clinical relevance of elevated CRP is worth discussing. This serum biomarker is mostly produced hepatically, triggered by acute and/or chronic inflammatory events. In the past years, CRP has been shown to play a key role in the management of inflammatory diseases such as cardiovascular diseases, neuro-degenerative diseases such as Alzheimer’s Disease (AD) and PD, or even periodontitis. In addition to activating the complement classical pathway, CRP also binds to several tissues and membranes propelling the inflammatory reaction through cytokines and nuclear antigens. In what PD concerns, this may be of importance because systemic and cerebral inflammation is increasingly cited in its pathophysiological basis regarded as a syndrome by many. Besides, neuroinflammation has been shown to be an important contributor to the pathogenesis of the Parkinsonian process and may aggravate the process of nigral neurodegeneration in animal models. Furthermore, in the periodontitis-PD link, and besides the established effects of PD impairments cause in oral health that may ultimately lead to the development of periodontitis, the infectious nature of periodontitis may have implications on gut microbiota which is known to be abnormal in PD.

Self-reported periodontitis is a validated, efficient, and accepted measure of periodontitis cases, with higher validity upon a combination of several self-report questions. In fact, the self-report strategy has been previously validated in other contexts, such as to identify cases of hypertension, diabetes mellitus, hypercholesterolemia, risk factors for cardiovascular disease, and even bruxism in PD patients. All in all, self-report enables larger scale epidemiologic studies and low-cost surveillance of symptoms, risk factors, and diseases of interest.

However, even though the periodontitis-leukocytosis link is well established—especially given the infectious nature of periodontitis whose effects summons WBC to the lesioned site—the self-reported “periodontitis” group presented slightly lower lymphocyte percentage when compared to the “without periodontitis” group. This can be explained through the fact that elevated levels of WBC would be more probable upon clinical diagnosis of periodontitis cases. Therefore, as the clinical periodontal diagnosis is far more preferable and reliable, the use of self-reported measures of periodontitis stands as a limitation in this study, even though this method has been previously validated and provides a cost-effective means of large-scale.
monitoring of oral health\textsuperscript{20}. Furthermore, disease severity and activity could not be appraised through a self-report method, which is also fully reliable on the patient’s knowledge of the disease and full awareness of a previous clinical diagnosis. Thus, the possibility of unmeasured confounding through this method of identification of periodontitis cases cannot be discarded\textsuperscript{21}.

Additionally, the sample size may be considered limited and thus a shortcoming of this study. Perhaps, this might be because we are trying to signpost an underappreciated condition of difficult diagnosis\textsuperscript{9}. Despite the small sample number, the collected data is of clinical significance, and we hope to pave the way for future larger studies on this condition worldwide (for instance using the MDS non-motor study group network). Also, the secondary study design based on the available NHANES data has been previously applied and accepted in several recent observational studies in Epidemiology (STROBE) guideline was followed (Table S1, Supplementary Materials)\textsuperscript{44}.

Nonetheless, due to the used PD-case selection method, data on disease duration was not available, which would have been relevant to evaluate disease staging. Furthermore, the observational nature of the study impairs the conclusion of causality, thus robust evidence has been reported regarding periodontitis increasing circulating levels of CRP and hs-CRP\textsuperscript{42}.

Table 1. General characteristics of PD patients according to the self-report of periodontitis.

| Variables                              | Self-reported Without Periodontitis (n = 28) | Periodontitis (n = 23) | p-value | Overall (n = 51) |
|----------------------------------------|---------------------------------------------|------------------------|---------|-----------------|
| Age (years), mean (SD)                 | 65.36 (14.79)                               | 60.04 (14.39)          | 0.133   | 62.96 (14.71)   |
| Females, n (%)                         | 14 (50.0)                                   | 10 (43.48)             | 0.855   | 24 (47.06)      |
| Ethnicity, n (%)                       |                                             |                        |         |                 |
| Mexican American                       | 1 (3.57)                                    | 1 (4.35)               | 0.352   | 2 (3.92)        |
| Other Hispanic                         | 1 (3.57)                                    | 4 (17.39)              | 5 (9.80) |                 |
| Non-Hispanic white                     | 17 (60.71)                                  | 14 (60.87)             | 31 (60.78) |               |
| Non-Hispanic black                     | 7 (25.00)                                   | 2 (8.70)               | 9 (17.65) |                 |
| Other Race—including multi-racial     | 2 (7.14)                                    | 2 (8.70)               | 4 (7.84)  |                 |
| Educational Level, n (%)               |                                             |                        |         |                 |
| <High school                           | 8 (28.57)                                   | 5 (21.74)              | 0.852   | 13 (25.49)      |
| High school                            | 5 (17.86)                                   | 3 (13.04)              | 8 (15.69) |                 |
| >High school                           | 15 (53.57)                                  | 15 (65.22)             | 30 (58.82) |               |
| Marital Status, n (%)                  |                                             |                        |         |                 |
| Single                                 | 8 (28.57)                                   | 3 (13.04)              | 0.025   | 11 (21.57)      |
| Married/Living with partner            | 14 (50.00)                                  | 15 (65.22)             | 29 (56.86) |               |
| Divorced/Separated/ Widowed            | 6 (21.43)                                   | 5 (21.74)              | 11 (21.57) |               |
| FI/PR, mean (SD)                       | 2.62 (1.71)                                 | 1.92 (1.46)            | 0.221   | 2.31 (2.08)     |
| Smoking status, n (%)                  |                                             |                        |         |                 |
| Non-smokers                            | 14 (50.00)                                  | 14 (60.87)             | 0.552   | 28 (54.90)      |
| Former smokers                         | 4 (14.29)                                   | 4 (17.39)              | 8 (15.69) |                 |
| Active smokers                         | 10 (35.71)                                  | 5 (21.74)              | 15 (29.41) |               |
| Chronic medical conditions, mean (SD)  | 2.75 (2.25)                                 | 5.91 (1.87)            | 0.406   | 2.55 (2.08)     |
| Diabetes, n (%)                        | 5 (17.86)                                   | 8 (34.78)              | 0.279   | 13 (25.49)      |
| Hba1c, mean (SD)                       | 6.03 (1.00)                                 | 5.91 (1.24)            | 0.064   | 5.98 (1.10)     |
| Hypertension, n (%)                    | 19 (67.86)                                  | 15 (65.22)             | 34 (66.67) |
| SBP, mean (SD)                         | 141.95 (25.29)                              | 129.86 (24.07)         | 0.173   | 136.50 (25.24)  |
| DBP, mean (SD)                         | 77.36 (12.39)                               | 70.15 (8.88)           | 0.176   | 74.11 (11.43)   |
| Missing teeth, mean (SD)              | 6.82 (6.60)                                 | 8.26 (6.66)            | 0.537   | 7.47 (6.60)     |

\textsuperscript{DBP Diastolic Blood Pressure, FI/PR Family income/poverty ratio, Hba1c Hemoglobin A1C level, n number of cases, SBP Systolic Blood Pressure, SD Standard Deviation.}

\textsuperscript{*Mann–Whitney test for continuous variables and Chi-square test for categorical variables.}

Hence, future research should continue to focus on the systemic repercussions of the periodontitis infection in PD patients, in the hopes of potentially clarifying the causality of the PD-periodontitis link. Furthermore, future research including in-depth clinical measures of periodontitis (such as periodontal pocket depth and clinical attachment loss), will provide further confirmation on the association with circulating systemic inflammatory surrogates.

METHODS

Study design

In this secondary study, data was extracted and further analyzed from the National Health and Nutrition Examination Survey (NHANES), a representative and stratified multistage health-related survey conducted on non-institutionalized U.S. citizens. The STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) guideline was followed (Table S1, Supplementary Materials)\textsuperscript{44}.

Setting, participants, and study size

Data from the NHANES 2015–2016 and 2017–2018 databases were used for the present study. Our analysis deemed the following inclusion criteria: 18 years of age or older; and undertaking secure PD medication regimens. Edentulous patients, missing data (on sociodemographic and/or systemic health information), and unsecure PD medication regimens as previously defined (Cabergoline, Orphenadrine, and Pramipexole)\textsuperscript{20} were excluded.
**Table 2.** Hematologic and biochemical levels of PD patients according to the self-report of periodontitis.

| Variables                        | Mean (SD) Without periodontitis | Mean (SD) Periodontitis | p-value* | Overall (n = 51) |
|----------------------------------|---------------------------------|-------------------------|----------|------------------|
| **Biochemical parameters, mean (SD)** |                                 |                         |          |                  |
| hs-CRP (mg/L)                    | 1.99 (2.03)                     | 5.36 (6.37)             | 0.031    | 3.51 (4.82)      |
| Total Cholesterol (mmol/L)       | 4.83 (0.82)                     | 4.58 (1.17)             | 0.389    | 4.71 (1.01)      |
| HDL-Cholesterol (mmol/L)         | 1.56 (0.56)                     | 1.35 (0.39)             | 0.515    | 1.46 (0.50)      |
| **Hematologic parameters, mean (SD)** |                               |                         |          |                  |
| WBC count (10^9/L)               | 6.88 (2.23)                     | 7.89 (2.24)             | 0.103    | 7.33 (2.31)      |
| Lymphocyte percent (%)           | 29.35 (11.83)                   | 28.03 (8.75)            | **0.007** | 28.76 (10.68)    |
| Monocyte percent (%)             | 8.81 (2.64)                     | 8.31 (2)                | 0.850    | 8.58 (2.41)      |
| Segmented neutrophils percent (%)| 58.16 (12.21)                   | 60.46 (9.05)            | 0.596    | 59.20 (11.07)    |
| Eosinophils percent (%)          | 2.87 (1.88)                     | 2.44 (1.21)             | 0.513    | 2.68 (1.64)      |
| Basophil percent (%)             | 0.95 (0.4)                      | 0.87 (0.29)             | 0.682    | 0.91 (0.36)      |
| Lymphocytes (10^9/L)             | 1.93 (0.77)                     | 2.17 (0.76)             | 0.214    | 2.04 (0.78)      |
| Monocytes (10^9/L)               | 0.57 (0.19)                     | 0.64 (0.02)             | 0.946    | 0.60 (0.20)      |
| Segmented neutrophils (10^9/L)   | 4.12 (1.86)                     | 4.83 (1.77)             | 0.142    | 4.44 (1.87)      |
| Eosinophils (10^9/L)             | 0.2 (0.15)                      | 0.2 (0.11)              | 0.696    | 0.20 (0.13)      |
| Basophils (10^9/L)               | 0.07 (0.05)                     | 0.07 (0.05)             | 0.886    | 0.07 (0.05)      |
| RBC count (10^12/L)              | 4.7 (0.4)                       | 4.65 (0.59)             | 0.643    | 4.68 (0.50)      |
| Hemoglobin (g/dL)                | 13.91 (1.42)                    | 13.5 (1.67)             | 0.872    | 13.73 (1.57)     |
| Hematocrit (%)                   | 41.92 (3.77)                    | 40.59 (4.42)            | 0.344    | 41.32 (4.17)     |
| Mean cell volume (fl)            | 89.29 (5.11)                    | 88.01 (9.34)            | 0.400    | 88.71 (7.43)     |
| Mean cell hemoglobin (pg)        | 29.62 (2.29)                    | 29.28 (3.76)            | 0.985    | 29.47 (3.07)     |
| Mean Cell Hgb Conc. (g/dL)       | 33.15 (0.95)                    | 33.2 (1.28)             | 0.519    | 33.17 (1.13)     |
| RCD width (%)                    | 14.28 (1.06)                    | 15.08 (1.55)            | 0.052    | 14.64 (1.37)     |
| Platelet count (1000 cells/uL)   | 248.46 (87.7)                   | 219.04 (77.86)          | 0.195    | 235.20 (85.52)   |
| MPV (fl)                         | 8.22 (0.77)                     | 8.33 (0.86)             | 0.726    | 8.27 (0.82)      |

* Mann–Whitney test.

WBC White Blood Cells, RBC Red Blood Cells, MCV Mean Cell Volume, MCH Mean Cell Hemoglobin, MCHC Mean Cell Hemoglobin Concentration, RCD Red Cell Distribution, MPV Mean Platelet Volume.

Detailed information on sampling, design, and medical records are displayed at [www.cdc.gov/nchs/nhanes.htm](http://www.cdc.gov/nchs/nhanes.htm) (accessed in April 2021). Health-related data-collection protocols from the NHANES 2015–2016 and 2017–2018 datasets underwent revision and approval by the Centers for Disease Control (CDC) and Prevention National Increase for Health Statistics Research (NCHS) Ethics Review Board, Atlanta USA, and all study participants provided written informed consent.

**Variables and data measurement**

**PD definition.** PD cases were identified in the NHANES database through the report of specific PD medications, according to a previous study. Hence, the reported use of Benzotropine, Carbipedia, Levodopa, Ropinirole, Methyldopa, Entacapone, and Amantadine were considered PD medications indicative of PD, therefore validating a PD case. Cabergoline, Orphenadrine, and Pramipexole all present other known clinical applications apart from PD-Cabergoline is used to treat high levels of prolactin hormone. Orphenadrine is used to treat muscle spasms in musculoskeletal conditions and Pramipexole is also used to treat restless legs syndrome (RLS)—and therefore were considered unsecure medications for the selection of PD cases.

**Periodontitis definition.** Periodontitis cases were pinpointed through a positive self-report on either one of the following oral health-related (OHR) questions, all regarding the moment when the survey was applied: “Do you think you might have gum disease?” “Ever had treatment for gum disease?” and “Ever been told of bone loss around teeth?”. This method of self-reporting periodontitis has been previously validated and is indicative of a periodontitis case.

**Demographic characteristics.** Age, gender, ethnicity, level of education, marital status, family income to poverty ratio, and smoking status were the self-reported sociodemographic variables collected and analyzed from NHANES datasets.

Regarding ethnicity, “Mexican American”, “Other Hispanic”, “Non-Hispanic White”, “Non-Hispanic Black” and “Other race—including multiracial” were the used designations, as indicated in the NHANES self-reported questionnaires.

The level of education in individuals aged over 20 was categorized as follows: “<high school” including <9th grade, 9–11th grade, and 12th grade with no diploma), “high school” (including high school grad/GED or equivalent) and “>high school” (including some college or AA degree and college graduate or above).

Concerning patients’ marital status, the used definition included “single” (never married), “married/living with a partner”, and “divorced/separated/widowed”.

With regards to the reported family income to poverty ratio, a continuous score from 0 to 5 was given: “0” corresponding to no income, “5” corresponding to an income 5 or more times above the federal poverty threshold.

At last, smoking status was defined as “active smokers” (reporting a consumption of ≥100 cigarettes during their lifetime and still currently smoking), “former smokers” (reporting smoking ≥100 cigarettes during their lifetime and presently ceased smoking) and non-smokers (reporting having smoked <100 cigarettes during their lifetimes).

**Health characteristics.** The systemic health status of the included participants was overall characterized through a sum of chronic medical conditions—asthma, psoriasis, gout, congestive heart failure, coronary
heart disease, angina, heart attack, stroke, emphysema, thyroid, bronchitis, liver, and cancer—which was statistically considered a continuous variable. Furthermore, Diabetes Mellitus (DM) was separately defined through self-report information and confirmed with glycated hemoglobin levels (HbA1c)\(^1\). Levels of HbA1c > 8% were considered uncontrolled DM cases\(^5\). Also, high blood pressure cases were defined from previous self-reports of medical-informed hypertension and were further confirmed with systolic and diastolic blood pressure levels (>140 mmHg and >90 mmHg, respectively)\(^6\).

**Blood and biochemical parameters.** Serum fractions of hs-CRP (mg/L), HDL-cholesterol (mg/dL), and total cholesterol were analyzed from blood specimens of the NHANES database\(^7\). Also, complete blood count with 5-part differential data was gathered, and information on white Blood Cell (WBC) count (10\(^9\)/L), percentage (\%), Lymphocyte (10\(^9\)/L), Monocyte (10\(^9\)/L), Segmented neutrophils (10\(^9\)/L), Neutrophils (%), percentage of Eosinophils (%), percentage of Basophils (\%), percentage of segmented Neutrophils (\%), percentage of Basophils (\%), percentage of segmented Neutrophils (\%), Eosinophil (10\(^9\)/L), Basophil (10\(^9\)/L), Red Blood Cell (RBC) count (10\(^12\)/L), Hemoglobin (g/dL), Hematocrit (\%), Mean Cell Volume (MCV) (FL), Mean Cell Hemoglobin (MCH) (pg), Mean Cell Hemoglobin Concentration (MCHC) (g/dL), Red Cell Distribution (RCD) width (%), Platelet count (1000 cells/\(\mu\)L) and Mean Platelet Volume (MPV) (FL) was analyzed. Blood collection occurred ~3 weeks following interviews, as detailed in https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/manuals.aspx?BeginYear=2015 (accessed in April 2021).

**Data management, analysis, and statistical methods**

Data analysis of the 2015–2016 and 2017–2018 NHANES datasets was conducted through IBM SPSS Statistics version 26.0.0.0 for Macintosh (Armonk, New York, IBM Corp.). Data were uploaded via SAS Universal Viewer and handled with Microsoft Excel. Continuous variables are reported through mean ± standard deviation (SD), while the number of cases (n) and percentage (%) represent categorical variables distribution among group categories. Upon assessment of data non-normality and homoscedasticity, Mann–Whitney test was applied for comparison of continuous variables. Chi-square test was used to evaluate association between the categorical variables. A 5% significance level was used in all inferential analyses.

**Reporting Summary**

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**DATA AVAILABILITY**

The analyzed data that supports the findings of this study are available in the NHANES database, a publicly accessible repository that does not issue DOIs, at https://wwwn.cdc.gov/nchs/nhanes.htm. The used datasets can be located under the “Survey Data and Documentation” tab, followed by the “NHANES 2015–2016” and “NHANES 2017–2018” databases tabs. “Demographics Data”, “Examination Data”, “Laboratory Data” and “Questionnaire Data” were consulted.

Received: 25 October 2021; Accepted: 10 March 2022; Published online: 13 April 2022

**REFERENCES**

1. Tynes, O.-B. & Storstein, A. Epidemiology of Parkinson’s disease. J. Neural Transm. 124, 901–905 (2017).
2. Ball, N., Teo, W.-P., Chandra, S. & Chapman, J. Parkinson’s disease and the environment. Front. Neurol. 10, 218 (2019).
3. Farrand, A. Q. et al. Vagus nerve stimulation improves locomotion and neuronal populations in a model of Parkinson’s disease. Brain Stimul. 10, 1045–1054 (2017).
4. Adams, B. et al. Parkinson’s disease: a systemic inflammatory disease accompanied by bacterial inflammagens. Front. Aging Neurosci. 10, 1–17 (2019).
5. Kalia, L. V. & Lang, A. E. Parkinson’s disease. Lancet 386, 896–912 (2015).
6. Qin, X. Y., Zhang, S. P., Cao, C., Loh, Y. P. & Cheng, Y. Aberrations in peripheral inflammatory cytokine levels in Parkinson disease: a systematic review and meta-analysis. JAMA Neurol. 73, 1316–1324 (2016).
7. van Vuuren, M. J., Nell, T. A., Carr, J. A., Kell, D. B. & Pretorius, E. Iron dysregulation and inflammagens related to oral and gut health are central to the development of Parkinson’s disease. Biomolecules 11, 1–27 (2021).
8. Poeoe, W. et al. Parkinson disease. Nat. Rev. Dis. Prim. 3, 17013 (2017).
9. Nakayama, Y., Washio, M. & Mori, M. Oral health conditions in patients with Parkinson’s disease. J. Epidemiol. 14, 143–150 (2004).
10. Schwartz, J., Heinrichs, E. & Storch, A. Increased periodontal pathology in Parkinson’s disease. J. Neurol. 253, 608–611 (2006).
11. Hanaoka, A. & Kashiha, K. Increased frequencies of caries, periodontal disease and tooth loss in patients with Parkinson’s disease. J. Clin. Neurosci. 16, 1279–1282 (2009).
12. Enarson, D. T. et al. Dental health of patients with Parkinson’s disease in a University Setting. Spec. Care Dent. 29, 123–127 (2009).
13. Ribeiro, G. R., Campos, C. H. & Rodrigues Garcia, R. C. M. Parkinson’s disease impacts masticatory function. Clin. Oral. Investig. 21, 1149–1156 (2017).
14. van Stiphout, M. A. E., Marinus, J., van Hulten, J. J., Lobbezoo, F. & De Baat, C. Oral health of Parkinson’s disease patients: a case-control study. Parkinsons. Dis. 2018, 1–8 (2018).
15. Martimbianco, A. L. C. et al. Evidence-based recommendations for the oral health of patients with Parkinson’s disease. Neurol. Ther. 10, 391–400 (2021).
16. Zlotnik, Y., Balash, Y., Korczyn, A. D., Giladi, N. & Gurlevich, T. Disorders of the oral cavity in Parkinson’s disease and parkinsonian syndromes. Parkinsons. Dis. https://doi.org/10.1155/2015/379482 (2015).
17. Auffret, M., Meuric, V., Boyer, E., Bonnare-Mallet, M. & Vérin, M. Oral health disorders in Parkinson’s disease: more than meets the eye. J. Parkinsons. Dis. 11, 1507–1535 (2021).

Hajishengallis, G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat. Rev. Immunol. 15, 30–44 (2015).

Slots, J. Periodontitis: facts, fallacies and the future. Periodontolo 2000 75, 7–23 (2017).

Blcher, B., Joshipura, K. & Eke, P. Validation of self-reported periodontal disease: a systematic review. J. Dent. Res. 84, 881–890 (2005).

Eke, P. I. et al. Self-reported measures for surveillance of periodontitis. J. Dent. Res. 92, 1041–1047 (2013).
38. Martin, L. M., Leff, M., Calonge, N., Garrett, C. & Nelson, D. E. Validation of self-reported chronic conditions and health services in a managed care population. Am. J. Prev. Med. 18, 215–218 (2000).
39. Bowlin, S. J. et al. Validity of cardiovascular disease risk factors assessed by telephone survey: the behavioral risk factor survey. J. Clin. Epidemiol. 46, 561–571 (1993).
40. Verhoef, M. C. et al. Is dopaminergic medication dose associated with self-reported bruxism in Parkinson’s disease? a cross-sectional, questionnaire-based study. Clin. Oral. Investig. 25, 2545–2553 (2021).
41. Kumar, B. P. et al. Association of chronic periodontitis with white blood cell and platelet count—a case control study. J. Clin. Exp. Dent. 6, 214–217 (2014).
42. Botelho, J. et al. Periodontitis and circulating blood cell profiles: a systematic review and meta-analysis. Exp. Hematol. 93, 1–13 (2021).
43. Lyra, P., Machado, V., Proença, L., Mendes, J. J. & Botelho, J. Tooth loss and blood pressure in Parkinson’s disease patients: an exploratory study on NHANES data. Int. J. Environ. Res. Public Health 18, 5032 (2021).
44. Von Elm, E. et al. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull. World Health Organ. 85, 867–872 (2007).
45. Eke, P. I., Page, R. C., Wei, L., Thornton-Evans, G. & Genco, R. J. Update of the case definitions for population-based surveillance of periodontitis. J. Periodontal. 83, 1449–1454 (2012).
46. Fox, S. H. et al. The movement disorder society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s disease. Mov. Disord. 26, 2–41 (2011).
47. Seppi, K. et al. The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov. Disord. 26, 42–80 (2011).
48. Sant’Anna, B. G. et al. A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas. Pituitary 23, 120–128 (2020).
49. Abd-Elsalam, S. et al. Orphenadrine in treatment of muscle cramps in cirrhotic patients: a randomized study. Eur. J. Gastroenterol. Hepatol. https://doi.org/10.1097/MEG.0000000000001622 (2020).
50. de Biase, S., Pellitteri, G., Gigli, G. L. & Valente, M. Advancing synthetic therapies for the treatment of restless legs syndrome. Expert Opin. Pharmacother. 20, 1971–1980 (2019).
51. Machado, V. et al. Association between dietary inflammatory index and periodontitis: a cross-sectional and mediation analysis. Nutrients https://doi.org/10.20944/preprints202011.0455.v1 (2020).
52. Escalda, C., Botelho, J., Mendes, J. J. & Machado, V. Association of bacterial vaginosis with periodontitis in a cross-sectional American nationwide survey. Sci. Rep. 11, 1–9 (2021).
53. Fontenot, K. R., Semega, J. L. & Kollar, M. A. US Census Bureau, Current Population Reports, P60-259, Income and Poverty in the United States: 2016. US Gov. Print. Off. Washington, DC https://www.census.gov/library/publications/2017/demo/p60-259.html (2017).
54. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. (WHO, 2001).
55. Casarin, R. C. V. et al. Subgingival biodiversity in subjects with uncontrolled type-2 diabetes and chronic periodontitis. J. Periodontal Res 48, 30–36 (2013).
56. Williams, B. et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur. Heart J. 39, 3021–3104 (2018).
57. Center for Disease Control and Prevention. National Health And Nutrition Examination Survey (NHANES): Laboratory Procedures Manual (2009). (Center for Disease Control and Prevention, accessed 6 May 2021); https://www.cdc.gov/nchs/data/nhanes/nhanes_09_10/lab.pdf
58. Center for Disease Control and Prevention. National Health And Nutrition Examination Survey (NHANES): MEC Laboratory Procedures Manual (2016). (Center for Disease Control and Prevention, accessed 6 May 2021); https://www.cdc.gov/nchs/data/nhanes/nhanes_15_16/2016_MEC_Laboratory_Procedures_Manual.pdf

AUTHOR CONTRIBUTIONS
Conceptualization, P.L., J.B., and V.M.; methodology, P.L., J.B. and V.M.; validation, J.B., V.M, S.R., L.P., and K.R.C.; formal analysis, P.L., J.B., S.R., and K.R.C.; investigation, P.L., J. B. and V.M.; resources J.B. and V.M; data curation, P.L. and J.B.; writing—original draft preparation, all authors; writing—review and editing, all authors; visualization, P.L. and J.B.; supervision, K.R.C. and J.J.M.; project administration, J.J.M.; All authors have read and agreed to the published version of the manuscript.

COMPETING INTERESTS
The authors declare no competing interests.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41531-022-00302-1.

Correspondence and requests for materials should be addressed to Patricia Lyra.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.